Fundamental Analysis of AQUESTIVE THERAPEUTICS INC(NASDAQ:AQST) stock

Fundamental Rating

Taking everything into account, AQST scores 2 out of 10 in our fundamental rating. AQST was compared to 198 industry peers in the Pharmaceuticals industry. AQST has a bad profitability rating. Also its financial health evaluation is rather negative. AQST is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AQST has reported negative net income.

In the past year AQST has reported a negative cash flow from operations.

In the past 5 years AQST always reported negative net income.

AQST had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

AQST has a Return On Assets of -13.71%. This is in the better half of the industry: AQST outperforms 70.26% of its industry peers.

		Industry Rank	Sector Rank
ROA	-13.71%
ROE	N/A
ROIC	N/A

ROA(3y)-74.28%

ROA(5y)-79.19%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AQST has a Gross Margin of 58.82%. This is in the better half of the industry: AQST outperforms 65.64% of its industry peers.

AQST's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for AQST so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	58.82%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-6.4%

GM growth 5Y-3.11%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AQST does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for AQST has been increased compared to 1 year ago.

Compared to 5 years ago, AQST has more shares outstanding

AQST has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -6.25, we must say that AQST is in the distress zone and has some risk of bankruptcy.

AQST has a worse Altman-Z score (-6.25) than 69.23% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-6.25

ROIC/WACCN/A

WACC9.25%

2.3 Liquidity

A Current Ratio of 2.24 indicates that AQST has no problem at all paying its short term obligations.

AQST's Current ratio of 2.24 is on the low side compared to the rest of the industry. AQST is outperformed by 62.56% of its industry peers.

A Quick Ratio of 1.87 indicates that AQST should not have too much problems paying its short term obligations.

The Quick ratio of AQST (1.87) is worse than 62.56% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.24
Quick Ratio	1.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AQST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.42%, which is quite impressive.

Looking at the last year, AQST shows a small growth in Revenue. The Revenue has grown by 6.07% in the last year.

AQST shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.59% yearly.

EPS 1Y (TTM)68.42%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q52.17%

Revenue 1Y (TTM)6.07%

Revenue growth 3Y3.33%

Revenue growth 5Y-5.59%

Revenue growth Q2Q23.65%

3.2 Future

The Earnings Per Share is expected to grow by 53.23% on average over the next years. This is a very strong growth

Based on estimates for the next years, AQST will show a very strong growth in Revenue. The Revenue will grow by 24.22% on average per year.

EPS Next Y-1.24%

EPS Next 2Y6.8%

EPS Next 3Y22.74%

EPS Next 5Y53.23%

Revenue Next Year2.48%

Revenue Next 2Y8.93%

Revenue Next 3Y20.72%

Revenue Next 5Y24.22%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AQST. In the last year negative earnings were reported.

Also next year AQST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

AQST's earnings are expected to grow with 22.74% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y6.8%

EPS Next 3Y22.74%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AQST does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AQUESTIVE THERAPEUTICS INC

NASDAQ:AQST (4/30/2024, 7:00:00 PM)

Premarket: 3.3012 -0.06 (-1.75%)

3.36

-0.37 (-10.04%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap286.27M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-13.71%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	58.82%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.88

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.24
Quick Ratio	1.87
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)68.42%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-1.24%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)6.07%

Revenue growth 3Y3.33%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

AQUESTIVE THERAPEUTICS INC (AQST)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens